Summary
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock?
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
AGEN trades below peers on sales multiples, but BOT+BAL's promise is offset by funding needs, dilution risk and a going-concern warning.
Agenus Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CAL CoreCap Advisors LLC CoreCap Advisors LLC | 2,000 | $9,140 | $6,780 | -$2,360 | -25.82% |
| AI Ana-Maria Ignat Covestor Ltd | 1,011 | $5,540.28 | $3,417.18 | -$2,123.1 | -38.32% |
| RAF Richard A. Flora Key Client Fiduciary Advisors LLC | 27,348 | $448,762.35 | $92,983.2 | -$355,779.15 | -79.28% |
| EW Ed West Values First Advisors Inc. | 11,065 | $175,621.63 | $37,621 | -$138,000.63 | -78.58% |
| DP Drew Phillips Fortitude Family Office LLC | 296 | $1,353 | $1,006.4 | -$346.6 | -25.62% |
Agenus Inc. (AGEN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Agenus Inc. ever had a stock split?
Agenus Inc. Profile
| Biotechnology Industry | Healthcare Sector | Garo H. Armen CEO | NASDAQ (CM) Exchange | 00847G804 CUSIP |
| US Country | 316 Employees | - Last Dividend | 12 Apr 2024 Last Split | 4 Feb 2000 IPO Date |
Overview
Agenus Inc. is a clinical-stage biotechnology company focusing on the discovery and development of immuno-oncology products, with operations spanning the United States and international markets. Established in 1994 and initially known as Antigenics Inc., the company underwent a rebranding to Agenus Inc. in January 2011. Situated in Lexington, Massachusetts, Agenus leverages its expertise in immuno-oncology to develop a broad array of therapeutic agents and vaccines aimed at treating various cancers. The company operates under several trademarks, including Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon. It also boasts strategic collaborations with leading pharmaceutical and biotechnology companies like Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc.
Products and Services
Retrocyte Display: This advanced antibody expression platform specializes in the identification of fully human and humanized monoclonal antibodies. Its technology facilitates the discovery and development of therapeutic antibodies with high specificity and efficacy.
QS-21 Stimulon: A saponin-based vaccine adjuvant used to enhance the body’s immune response to vaccines. QS-21 Stimulon is part of the company's adjuvant portfolio aimed at improving the effectiveness of vaccines against infectious diseases and cancers.
Balstilimab: An anti-PD-1 antagonist currently in Phase II clinical trials for the treatment of second-line cervical cancer. This product represents Agenus' efforts to advance the treatment options available for cervical cancer patients.
AGEN1181: A CTLA-4 blocking antibody under Phase 2 clinical trial aiming to treat conditions such as pancreatic cancer and melanoma. AGEN1181 showcases the company’s commitment to developing treatments for hard-to-treat cancers.
AGEN2373: A CD137 monospecific antibody in Phase 1b clinical trial, representing the company's work in targeting specific cancer cell proteins to enhance the immune system's ability to fight cancer.
AGEN1423: This CD73/TGFß TRAP antibody is part of Agenus’ portfolio geared towards inhibiting cancer growth and proliferation.
AGEN1571: An ILT2 monospecific antibody in Phase 1 clinical trial, showcasing the company’s exploration of novel targets to stimulate an immune response against cancer cells.
BMS-986442: A TIGIT bispecific antibody developed in collaboration with Bristol-Myers Squibb, highlighting Agenus' expertise in bi-specific antibody development.
Other Products: The company is also developing INCAGN1876 (GITR agonist), INCAGN2390 (TIM-3 monospecific antibody), INCAGN2385 (LAG-3 monospecific antibody), MK-4830 (an ILT4 targeting monospecific antibody in Phase 2 trial), UGN-301 (a zalifrelimab intravesical solution for urinary tract cancers in Phase 1 trial), and AGEN1884 (a first-generation anti-CTLA-4 monospecific antibody). These products underscore Agenus’ diverse approach to fighting cancer through various pathways and mechanisms.
